cholecalciferol and Fatigue-Syndrome--Chronic

cholecalciferol has been researched along with Fatigue-Syndrome--Chronic* in 2 studies

Trials

1 trial(s) available for cholecalciferol and Fatigue-Syndrome--Chronic

Article	Year
Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome--a randomised controlled trial. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:3 Low 25-hydroxyvitamin D levels are common in patients with chronic fatigue syndrome; such patients also manifest impaired vascular health. We tested whether high-dose intermittent oral vitamin D therapy improved markers of vascular health and fatigue in patients with chronic fatigue syndrome.. Parallel-group, double-blind, randomised placebo-controlled trial. Patients with chronic fatigue syndrome according to the Fukuda (1994) and Canadian (2003) criteria were randomised to receive 100,000 units oral vitamin D3 or matching placebo every 2 months for 6 months. The primary outcome was arterial stiffness measured using carotid-femoral pulse wave velocity at 6 months. Secondary outcomes included flow-mediated dilatation of the brachial artery, blood pressure, cholesterol, insulin resistance, markers of inflammation and oxidative stress, and the Piper Fatigue scale. As many as 50 participants were randomised; mean age 49 (SD 13) years, mean baseline pulse wave velocity 7.8 m/s (SD 2.3), mean baseline office blood pressure 128/78 (18/12) mmHg and mean baseline 25-hydroxyvitamin D level 46 (18) nmol/L. 25-hydroxyvitamin D levels increased by 22 nmol/L at 6 months in the treatment group relative to placebo. There was no effect of treatment on pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% CI -0.6 to 0.6; p = 0.93). No improvement was seen in other vascular and metabolic outcomes, or in the Piper Fatigue scale at 6 months (adjusted treatment effect 0.2 points; 95% CI -0.8 to 1.2; p = 0.73).. High-dose oral vitamin D3 did not improve markers of vascular health or fatigue in patients with chronic fatigue syndrome.. www.controlled-trials.com, ISRCTN59927814. Topics: Adult; Biomarkers; Blood Pressure; Brachial Artery; Canada; Cardiovascular Physiological Phenomena; Cholecalciferol; Cholesterol; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue Syndrome, Chronic; Female; Humans; Inflammation; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness; Vitamin D Deficiency	2015

Article

Year

Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome--a randomised controlled trial.

Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:3

Low 25-hydroxyvitamin D levels are common in patients with chronic fatigue syndrome; such patients also manifest impaired vascular health. We tested whether high-dose intermittent oral vitamin D therapy improved markers of vascular health and fatigue in patients with chronic fatigue syndrome.. Parallel-group, double-blind, randomised placebo-controlled trial. Patients with chronic fatigue syndrome according to the Fukuda (1994) and Canadian (2003) criteria were randomised to receive 100,000 units oral vitamin D3 or matching placebo every 2 months for 6 months. The primary outcome was arterial stiffness measured using carotid-femoral pulse wave velocity at 6 months. Secondary outcomes included flow-mediated dilatation of the brachial artery, blood pressure, cholesterol, insulin resistance, markers of inflammation and oxidative stress, and the Piper Fatigue scale. As many as 50 participants were randomised; mean age 49 (SD 13) years, mean baseline pulse wave velocity 7.8 m/s (SD 2.3), mean baseline office blood pressure 128/78 (18/12) mmHg and mean baseline 25-hydroxyvitamin D level 46 (18) nmol/L. 25-hydroxyvitamin D levels increased by 22 nmol/L at 6 months in the treatment group relative to placebo. There was no effect of treatment on pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% CI -0.6 to 0.6; p = 0.93). No improvement was seen in other vascular and metabolic outcomes, or in the Piper Fatigue scale at 6 months (adjusted treatment effect 0.2 points; 95% CI -0.8 to 1.2; p = 0.73).. High-dose oral vitamin D3 did not improve markers of vascular health or fatigue in patients with chronic fatigue syndrome.. www.controlled-trials.com, ISRCTN59927814.

Topics: Adult; Biomarkers; Blood Pressure; Brachial Artery; Canada; Cardiovascular Physiological Phenomena; Cholecalciferol; Cholesterol; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue Syndrome, Chronic; Female; Humans; Inflammation; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness; Vitamin D Deficiency

2015

Other Studies

1 other study(ies) available for cholecalciferol and Fatigue-Syndrome--Chronic

Article	Year
Tired with all those supplements? QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Cholecalciferol; Dietary Supplements; Diphosphonates; Fatigue Syndrome, Chronic; Female; Fluid Therapy; Humans; Pamidronate; Treatment Outcome; Vitamin D	2011